Pain News and Research

Latest Pain News and Research

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

NIH begins human clinical testing for dengue virus vaccine

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

10 Aug 2010

Sleeve gastrectomy for weight loss surgery with no scars

Surgeons at the University of California, San Diego School of Medicine have achieved what is believed to be the nation's first stomach reduction via the mouth. The novel weight loss procedure, known as a sleeve gastrectomy, reduces the stomach to 20 percent of its original size. The smaller stomach leads to less caloric intake and increased feelings of fullness. This is the first time in the U.S. that the excess stomach has been removed through the mouth rather than a large open incision.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Vena cava blood clot filters may cause potential life-threatening complications: Study

Two specific types of vena cava filters, devices used to prevent blood clots from reaching the lungs, appear to have evidence of fracturing inside the body, with some fractured fragments traveling to the heart and causing potentially life-threatening complications, according to a report posted online today that will appear in the November 8 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Aug 2010

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.

9 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today a national agreement with MultiPlan, the nation's leading comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan Networks, Millennium Laboratories will assist participating physicians with state-of-the-art therapeutic drug monitoring services and tools.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

45-year-old Hummelstown patient takes on FDA over Johnson & Johnson’s antibiotic Levaquin

Suffering from injuries to his brain, nerves, and tendons for over four years, 45-year-old John Fratti of Hummelstown, PA, has taken on the Food and Drug Administration with good results. Since taking Johnson & Johnson’s antibiotic Levaquin for an infection he has had many diagnostic studies on his brain and body that show considerable damage. Healthy and athletic at 41 years of age, he now takes multiple prescription pain medications for his injuries.

7 Aug 2010

Ironwood provides investor update for second-quarter 2010

Ironwood Pharmaceuticals, Inc. today provided an update on its business activities for the second quarter of 2010.

7 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

BMS to join ranks of AIDS drug companies to offer price concessions

Bristol-Myers Squibb will soon announce an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide. The agreement, with the ADAP Crisis Task Force (ACTF) of the National Alliance of State & Territorial AIDS Directors, is expected to be announced any day. BMS has been the target of a sustained advocacy campaign led by AHF over its pricing of its key AIDS drug Reyataz.

7 Aug 2010

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Results from a randomized study with Zyclara following cryotherapy in the treatment of actinic keratoses (AK) demonstrated Zyclara complemented the effectiveness of cryosurgery in reducing total AK count and achieving complete clearance of AK, according to data presented at the American Academy of Dermatology Summer Academy Meeting 2010 (Summer AAD), August 4 - 8.

7 Aug 2010

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its second quarter ended June 30, 2010.

7 Aug 2010

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

A new study by researchers at the UC Davis School of Medicine has found that psychiatrists can accurately assess a patient's mental health by viewing videotaped interviews that are sent to them for consultation and treatment recommendations.

7 Aug 2010

Scientists develop hand prosthesis that eases phantom pain

The pain of losing a body part is twofold, as the patients not only suffer from wound pain. Often they are also affected by so called phantom pain. Unlike bodily wounds which will eventually heal, phantom pain often lasts for years and sometimes a lifetime. "Phantom pain is very difficult to treat", says Professor Dr Thomas Weiss from the Friedrich-Schiller-University Jena.

7 Aug 2010

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

A newly discovered molecular mechanism helps control the amount and effectiveness of a substance that mimics an active ingredient in marijuana, but that is produced by the body's own nerve cells.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

Pain News and Research

Latest Pain News and Research

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Endo to acquire Penwest for $5.00 per share

NIH begins human clinical testing for dengue virus vaccine

Sleeve gastrectomy for weight loss surgery with no scars

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Vena cava blood clot filters may cause potential life-threatening complications: Study

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

Progenics second-quarter total revenue decreases to $2.3 million

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Lexicon Pharmaceuticals updates key progress in clinical pipeline

45-year-old Hummelstown patient takes on FDA over Johnson & Johnson’s antibiotic Levaquin

Ironwood provides investor update for second-quarter 2010

EpiCept second-quarter net loss decreases to $4.9 million

BMS to join ranks of AIDS drug companies to offer price concessions

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

Scientists develop hand prosthesis that eases phantom pain

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

OncoGenex reports net income in second-quarter 2010 against loss last year

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Pain News and Research

Latest Pain News and Research

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Newsletters you may be interested in